DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Orthoclone Okt3 (Muromonab-CD3) - Summary

 
 



WARNING:

Only physicians experienced in immunosuppressive therapy and management of solid organ transplant patients should use ORTHOCLONE OKT3 (muromonab-CD3). Patients treated with ORTHOCLONE OKT3 must be managed in a facility equipped and staffed for cardiopulmonary resuscitation and where the patient can be closely monitored for an appropriate period based on his or her health status.

Anaphylactic and anaphylactoid reactions may occur following administration of any dose or course of ORTHOCLONE OKT3. In addition, serious, occasionally life-threatening or lethal, systemic, cardiovascular, and central nervous system reactions have been reported following administration of ORTHOCLONE OKT3. These have included: pulmonary edema, especially in patients with volume overload; shock, cardiovascular collapse, cardiac or respiratory arrest, seizures, coma, cerebral edema, cerebral herniation, blindness, and paralysis. Fluid status should be carefully monitored prior to and during ORTHOCLONE OKT3 administration. Pretreatment with methylprednisolone is recommended to minimize symptoms of Cytokine Release Syndrome. (See: WARNINGS: Cytokine Release Syndrome, Central Nervous System Events, Anaphylactic Reactions ; DOSAGE AND ADMINISTRATION.)

 

SUMMARY

ORTHOCLONE OKT3 (muromonab-CD3) Sterile Solution is a murine monoclonal antibody to the CD3 antigen of human T cells which functions as an immunosuppressant. It is for intravenous use only.

ORTHOCLONE OKT3 is indicated for the treatment of acute allograft rejection in renal transplant patients.

ORTHOCLONE OKT3 is indicated for the treatment of steroid-resistant acute allograft rejection in cardiac and hepatic transplant patients.

The dosage of other immunosuppressive agents used in conjunction with ORTHOCLONE OKT3 should be reduced to the lowest level compatible with an effective therapeutic response. (See: WARNINGS and ADVERSE EVENTS: Infections, Neoplasia ; DOSAGE AND ADMINISTRATION.)


See all Orthoclone Okt3 indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Orthoclone Okt3 (Muromonab-CD3)

Cardiovascular side effects after renal allograft rejection therapy with Orthoclone: prevention with nitrendipine. [1991]
Orthoclone (OKT-3), a monoclonal antibody, is an effective immunosuppressant in organ graft recipients... In group b (patients receiving 2 x 10 mg of nitrendipine before OKT-3 therapy was started and during the whole treatment course), in 3 of 13 patients, a short increase in blood pressure (13.7 +/- 2.9/7.8 +/- 5.1 mm Hg) was recorded 5 h after the first dose of OKT-3.(ABSTRACT TRUNCATED AT 250 WORDS).

Muromonab-CD3 for the successful treatment of early chronic rejection after pediatric liver transplantation: report of a case. [2011.04]
A four-and-a-half-year-old boy underwent living-donor liver transplantation (LDLT) for progressive familial intrahepatic cholestasis. Immunosuppressive therapy was commenced with tacrolimus and methylprednisolone, despite which derangement of liver function tests (LFTs) became evident on postoperative day (POD) 7.

Muromonab-CD3 therapy for refractory rejections after liver transplantation: a single-center experience during two decades in Japan. [2010.11]
BACKGROUND/PURPOSE: Refractory rejections still occur in the liver transplantation (LT) field. The aim of this study was to investigate significant factors for the introduction of therapy with muromonab-CD3 (MCD3) after LT... CONCLUSION: Optimal induction of MCD3 triggered recovery from refractory rejections, especially in LT recipients in a stable condition, but not in those in a critical or compromised condition.

[From orthoclone to denosumab, the fast growing market of monoclonal antibodies] [2009.12]
Monoclonal antibodies are a specific medicinal category within the current therapeutic armamentarium. Their market share is growing fast as they are often the only therapeutic option at some stages of certain diseases, due to their targeted action in the body and to an acceptable tolerance... The launch of biosimilars after patent expiry of some of these drugs will take time in view of the complexity of these molecules, and is not likely to significantly impact the cost of these therapies.

Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation. [2006.09]
We report the results of a prospective non-randomized phase II study of Muromonab-CD3 (Orthoclone OKT3), an anti-CD3 monoclonal antibody, with methylprednisolone (MP) and cyclosporine (CSA) for acute GVHD (aGVHD) prophylaxis in 22 hematologic malignancy patients... OKT3+MP+CSA combination is moderately effective aGVHD prophylaxis, however, it is unlikely to be superior to CSA+MTX.

more studies >>

Clinical Trials Related to Orthoclone Okt3 (Muromonab-CD3)

Oral OKT3 for the Treatment of Active Ulcerative Colitis [Recruiting]
This study will assess the safety and efficacy of orally delivered short-term OKT3 in patients with active ulcerative colitis.

Oral OKT3 in Combination With Beta-D-Glucosylceramide [Recruiting]
This clinical study is designed to evaluate the safety of oral administration of the study drug anti CD3 (OKT3) in combination with β-D glucosylceramide [GC] .

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies [Recruiting]
Patients with refractory hematologic malignancies including those who develop recurrent disease after allogeneic hematopoietic stem cell transplantation (HSCT) have a dismal prognosis. Historically, both regimen-related mortality and disease recurrence have been significant causes of treatment failure in this heavily pre-treated patient population. The investigators institution has utilized mismatched family member donors for these patients for several reasons: (1) Only 30% of patients have matched related donors available; (2) transplantation can be performed more rapidly since the time to unrelated donor trans-plantation averages 3 to 4 months; (3) the alloimmune reactivity of natural killer (NK) cells following haploidentical HSCT has been shown to reduce relapse rates in certain patient groups; and, (4) no other curative treatment options are available.

In the present trial, the investigators propose a novel conditioning regimen using clofarabine in an effort to enhance cytotoxicity while simultaneously reducing regimen related toxicity. In this phase I trial, the goal is to determine the maximum tolerated dose (MTD) of clofarabine when used in combination with melphalan and thiotepa pre-transplant.

Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis [Recruiting]
This is a study to determine the efficacy of muromonab-CD3 and cyclosporine as treatment in patients with giant cell myocarditis (GCM). T lymphocytes appear to be involved in GCM. Muromonab-CD3 has been shown to reduce the number of lymphocytes and cyclosporine inhibits lymphocyte activation. This treatment may prolong patient survival until transplantation or ventricular assist device placement is possible.

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases [Recruiting]
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell and donor natural killer cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When certain stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Removing the T cells from the donor cells before transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well giving a donor peripheral stem cell transplant and a donor natural killer cell transplant after total-body irradiation, thiotepa, fludarabine, and muromonab-CD3 works in treating patients with leukemia or other blood diseases.

more trials >>

Reports of Suspected Orthoclone Okt3 (Muromonab-CD3) Side Effects

Abdominal Pain (2)Kidney Transplant Rejection (2)Constipation (2)Abdominal Tenderness (2)Abdominal Discomfort (2)Peritonitis Bacterial (2)Epstein-Barr Virus Associated Lymphoproliferative Disorder (2)Gastrointestinal Sounds Abnormal (2)Renal Graft Loss (2)Staphylococcal Skin Infection (2)more >>


Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014